A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the ...

More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests SOUTH SAN FRANCISCO, ...

The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed ...

Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026 ...

MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S. commercial launch of PROSTOX™ Standard, a new, clinically validated genetic ...

We performed a post hoc analysis of a single-center phase II trial (ClinicalTrials.gov identifier: NCT03503643) in which patients with unilateral grade group (GG) 2-4 PCa (n = 108) underwent hemigland ...

Findings are from the multicenter, prospective, Phase 3 STAMPEDE trial “Our findings suggest that the Decipher Prostate test may provide an important new tool to help guide treatment decisions for the ...